Participated · Series B · Aug 2026

Expedition Therapeutics is developing next-generation oral small molecule therapies targeting inflammatory and respiratory diseases, with its lead program EXPD-101, a once-daily DPP1 inhibitor, currently in a global Phase 2 trial for COPD. The company reported that EXPD-101 was well tolerated in Phase 1 with no dose-limiting toxicities and showed dose-proportional pharmacokinetics supporting once-daily dosing. The first patient has been dosed in the Phase 2 COPD study, marking the company’s transition into mid-stage clinical development. Expedition combines translational expertise and clinical development experience with a platform for in-licensing global innovation. The recent $115 million Series B financing led by General Atlantic is intended to fund EXPD-101 through Phase 2, expand the company’s pipeline of therapies for inflammatory diseases, and further its research discovery efforts. Expedition is based in San Francisco and has announced board expansion tied to the financing.

Participated · Series B · Jul 2026

Claris Biotherapeutics, spun out of the Harvard lab of corneal disease expert Reza Dana, is developing CSB-001 (oremepermin alfa), an eye drop candidate now targeted at limbal stem cell deficiency (LSCD) after an initial neurotrophic keratitis study failed but showed benefit in LSCD patients. The company plans a phase 3 pivotal trial of CSB-001 beginning in the first half of 2027 with a data readout expected within roughly two years. Claris is running a non-interventional natural history study to better understand LSCD and to create a pool of subjects for its phase 3 trial. The biotech has grown from an initial team of five to more than 25 employees and is seeking to establish a physical headquarters. CEO Stephen Brady, who took over June 15, said the company intends to educate providers on diagnosing LSCD and expects to explore additional indications or pipeline expansion if independent and capitalized. Brady also anticipates taking the company public before phase 3 readout, either via IPO or a reverse merger.

Participated · Series B · Jun 2026

City Therapeutics is developing a pipeline of RNA interference (RNAi) therapeutics using a next‑generation RNAi engineering platform. The company has initiated a Phase 1 clinical trial of CITY‑FXI targeting Factor XI and reported positive preclinical data for CITY‑RBP4, a candidate for Stargardt disease. It has announced strategic collaborations with Bausch + Lomb and Biogen and plans to advance two programs to clinical stage this year while progressing additional programs toward the clinic by year‑end 2026. City Therapeutics is based in Cambridge, MA, and has raised over $230 million from life sciences investors to date. The recent $99.5 million Series B is intended to accelerate its platform, expand the pipeline, and support business development and partnership activities.

Participated · Series A · Apr 2026

Coultreon Biopharma focuses on developing therapies that target clinically validated pathways in immunology and metabolic diseases, leveraging expertise in disease biology, drug discovery and translational science. Its pipeline centers on selectively modulating salt-inducible kinase (SIK) biology to address key inflammatory pathways. The company's lead program, COL-5671 (formerly O3R-5671), is a highly selective, oral once-daily SIK3 inhibitor currently in Phase 1 clinical studies. Coultreon intends to use the $125M Series A proceeds to support further clinical development of COL-5671. The company is led by CEO Pierre Raboisson and is based in Leuven, Belgium. No revenue, user, founding year or prior-round financial metrics were reported in the article.

Participated · Series A · Feb 2026

Verley engineers beta-lactoglobulin (BLG) whey proteins through precision fermentation, selling them under the FermWhey™ range to manufacturers looking for high-protein, clean-label and easily digestible ingredients. The proteins are functionalized to improve solubility, emulsification, gelling and nutritional profiles, enabling applications such as high-protein yoghurts and protein shots. By using fermentation rather than conventional dairy production, Verley claims to cut natural-resource consumption and help alleviate structural supply constraints in traditional whey. In less than four years, the company has secured self-affirmed GRAS status (2024) and an FDA “No Questions” letter (2025), validating product safety for the U.S. market. Verley holds a growing IP portfolio around both fermentation and protein functionalisation technologies that aim to outperform standard dairy proteins. The fresh capital will fund U.S. commercial rollout, early customer scale-up and increased production capacity, followed by planned expansion in Europe and the Middle East. Continued R&D investment is earmarked to push performance, efficiency and sustainability of its platform.